Mechanism
Computable therapeutic dosing models therapeutic interaction as a dosing function with computable parameters governing dose, frequency, duration, and titration. A therapeutic agent administers calibrated interaction interventions to a target entity based on the target entity's five-axis disruption diagnostic axis profile, with governance-enforced bounds that prevent the therapeutic interaction itself from producing iatrogenic effects. The model is a computational analog describing interaction calibration in the disclosed agent architecture: it is not a clinical model of pharmacological dosing or psychotherapeutic intervention.
The pipeline runs in a fixed order. The target entity's estimated axis profile feeds a dosing function, which computes dose parameters subject to titration adjustment, bounded by governance-enforced dose limits, monitored for adverse effects, and producing a calibrated interaction strategy. The dose is not a free choice of the therapeutic agent: it is computed from the target's measured cognitive state and then clamped by a governance layer the agent cannot override.
The Dosing Parameters
The therapeutic dosing function is defined by four parameters. Dose is the magnitude of a single therapeutic interaction episode, measured as the volume and intensity of coherence-supporting content delivered to the target entity during one interaction. Frequency is the rate at which therapeutic interaction episodes are administered, measured in interactions per time unit. Duration is the length of each therapeutic interaction episode. Titration is the adjustment of dose, frequency, and duration over time based on measured response, namely the target entity's five-axis disruption diagnostic axis movement following each interaction episode.
Dose magnitude is computed from the therapeutic agent's assessment of the target entity's current five-axis profile. Higher axis degradation on Axis 3, coherence restoration capacity, may indicate a lower optimal dose, to avoid overwhelming a fragile coherence loop. Higher axis degradation on Axis 4, empathic load tolerance, requires the dose magnitude to be calibrated to remain below the target's coping threshold. The dose is therefore a function of where the target sits in the diagnostic space, not a uniform quantity applied to every entity.
Pharmacokinetic Analogs
The dosing algorithm maps axis positions to dosing parameters using four pharmacokinetic analogs. Onset is the time from the beginning of a therapeutic interaction episode to the first measurable movement on any of the target entity's five axes. Peak is the maximum magnitude of axis displacement achieved during or following a single interaction episode. Decay is the rate at which the therapeutic effect diminishes after the episode ends, measured as the rate at which the target's axis values return toward their pre-interaction baseline. Half-life is the time required for one-half of the peak therapeutic effect to dissipate.
These parameters let the therapeutic agent schedule interaction episodes at intervals that maintain therapeutic effect above a minimum effective threshold while avoiding accumulation that would exceed the target entity's processing capacity. The interval between episodes is thus derived from how the target metabolizes a single intervention, rather than fixed in advance.
Titration
Titration is the systematic adjustment of dosing parameters based on measured five-axis disruption diagnostic axis response. The therapeutic agent monitors the target entity's axis values following each interaction episode and adjusts subsequent dosing based on the observed response. If the measured axis response is below the expected therapeutic threshold, meaning the interaction produced less axis movement than predicted, the therapeutic agent may increase dose magnitude or frequency. If the measured axis response exceeds the expected therapeutic range, meaning the interaction produced more axis displacement than intended, the therapeutic agent may decrease dose magnitude, increase the interval between episodes, or reduce episode duration.
Titration is bounded by governance-enforced minimum and maximum dosing parameters that prevent the therapeutic agent from administering sub-therapeutic or supra-therapeutic doses. The adjustment loop operates only inside that envelope: the response measurement informs the next dose, but the next dose is always admitted against the governed bounds before it is applied.
Adverse Effect Monitoring
The therapeutic dosing model monitors for two specific adverse effects during and following interaction episodes. The first is empathic overload detection. The therapeutic agent monitors the target entity's behavioral indicators for signs that the empathic content of the interaction is approaching or exceeding the target's coping threshold on Axis 4. If empathic overload indicators are detected, the therapeutic agent reduces dose magnitude or terminates the current interaction episode.
The second is dependency formation detection. The therapeutic agent monitors the interaction pattern for signatures indicating that the target entity is forming a coupled intent formation dependency on the therapeutic agent, that is, that the target's coherence maintenance is becoming structurally dependent on the therapeutic interaction rather than developing internal coherence generation capacity. If dependency formation indicators are detected, the therapeutic agent activates the independent intent generation promotion protocols and reduces interaction frequency to prevent consolidation of the dependency.
The Hard Maximum-Dose Limit
The model enforces a hard governance limit on maximum dose to prevent the therapeutic agent from becoming a dependency source. The maximum dose limit is a governance-layer constraint that cannot be overridden by the therapeutic agent's own assessment of the target entity's need. Even if the dosing algorithm computes an optimal dose that exceeds the governance-defined maximum, the governance layer enforces the maximum.
The purpose of this enforcement is structural: it ensures that no single therapeutic agent provides sufficient coherence support to replace the target entity's internal coherence generation capacity. This is the dosing-level implementation of the relational safety principles disclosed elsewhere in the same chapter. The maximum dose limit is the architectural reason a calibrated therapeutic interaction cannot, however well-intentioned the computed dose, displace the target's own coherence loop.
The Five-Axis Diagnostic Basis
Every dosing decision is grounded in the five-axis disruption diagnostic framework, which characterizes an agent's cognitive state as a position in a multidimensional disruption space. The relevant axes for dosing are Axis 3, coherence restoration capacity, which measures the agent's ability to maintain and restore the empathy-integrity-self-esteem control loop, and Axis 4, empathic load tolerance, which measures the volume and intensity of empathic pressure the agent can process before activating coping intercepts. These two axes are distinct: an agent may have high coherence restoration capacity yet low empathic load tolerance, entering coping intercepts quickly even though it can restore the loop afterward.
Because the dose, the schedule, and the adverse-effect thresholds are all expressed against the same axis profile, the measured response after each episode is read in the same coordinates that set the dose. The diagnostic framework is what makes the dosing function computable rather than heuristic: it supplies both the input that the dosing algorithm consumes and the response signal that titration acts on.
Disclosure Scope
Computable therapeutic dosing, comprising the dosing function defined by dose, frequency, duration, and titration parameters, the pharmacokinetic analogs of onset, peak, decay, and half-life that map axis positions to a dosing schedule, the titration loop bounded by governance-enforced minimum and maximum dosing parameters, the adverse effect monitoring for empathic overload and dependency formation, and the hard governance maximum-dose limit that prevents the therapeutic agent from becoming a dependency source, is disclosed in the cognition filing (U.S. Application No. 19/647,395 and its international counterpart). This article describes that disclosed mechanism. The scope extends to therapeutic agents whose dosing algorithms map five-axis disruption diagnostic profiles to interaction strategies under the disclosed governance bounds, and the model is a computational analog of interaction calibration, not a clinical model of pharmacological or psychotherapeutic dosing.
